528587-95-3

Upstream product

• 925-90-6 ethylmagnesium bromide 
• 528587-87-3 (1S,2R)-1-(4-fluorophenyl)-2-formyl-N,N-diethylcyclopropanecarboxamide 
• 528587-79-3 (1S,2R)-1-(4-fluorophenyl)-2-(hydroxymethyl)-N,N-diethylcyclopropanecarboxamide 
• 528587-71-5 (1S,5R)-2-oxo-1-(4-fluorophenyl)-3-oxabicyclo[3.1.0]hexane 
• 459-22-3 4-fluorophenylacetonitrile 

Downstream Products

• 528588-03-6 (1S,2R)-1-(4-fluorophenyl)-2-[(S)-1-azidopropyl]-N,N-diethylcyclopropanecarboxamide 
• 528588-19-4 (1S,4S,5R)-2-oxo-4-ethyl-1-(4-fluorophenyl)-3-oxabicyclo[3.1.0]hexane 

Relevant academic research and scientific papers

Synthesis of derivatives of (1S,2R)-1-phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopropanecarboxamide (PPDC) modified at the 1-aromatic moiety as novel NMDA receptor antagonists: The aromatic group is essential for the activity

(1S,2R)-1-Phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopropanecarboxamide (PPDC, 4a), which is a conformationally restricted analogue of antidepressant milnacipran [(±)-1], is a new class of potent noncompetitive NMDA receptor antagonists. A series of PPD